The Medicines and Healthcare products Regulatory Agency (MHRA) has approved tisotumab vedotin (Tivdak), an innovative intravenous therapy for adults with recurrent or metastatic cervical cancer.
The treatment is administered once every three weeks, with each infusion lasting approximately 30 minutes. It is also intended for patients whose cancer has worsened following previous anti-cancer therapies.
Cervical cancer causes nearly 685 deaths annually in England, according to NHS England.
“The approval of tisotumab vedotin provides a new treatment option for adults with cervical cancer. As with all licensed medicines, we will continue to monitor its safety closely as it becomes more widely used,” said Julian Beach, interim executive director of Healthcare Quality and Access at the MHRA.
Common side effects include eye problems such as conjunctivitis and keratitis, and nerve issues like numbness, tingling, or burning in the hands and feet.
A full list of side effects will be published in the Patient Information Leaflet (PIL) and the Summary of Product Characteristics (SmPC) on the MHRA website within a week.
Related topic：
